Patients deserve the best
CIRCULOGENE is the most comprehensive blood-based approach to detecting clinically significant tumor DNA/RNA alterations. 25,000 cancer patients have benefited from our innovative, best-in-class liquid biopsy. Our novel approach has created unique liquid biopsy tests which aids oncologists to personalize and monitor the patient’s treatment plan with the goal of better outcomes and survival.
CIRCULOGENE begins with a patented Linear In Situ Amplification (LISA) methodology which effectively preserves and extracts fragile RNA. Our use of next-generation sequencing (NGS) and polymerase chain reaction (PCR) instrumentation provides both the breadth of DNA menu and the depth for RNA detection. These two technological advancements are the basis for our best-in-class menu offerings, including TumorClear, ImmunoClear, MSI Complete, and Hereditary Panels.
CIRCULOGENE can complement tissue biopsy as recommended by the International Association for the Study of Lung Cancer (IASLC) for enabling a faster time to treatment, providing the right first-line treatment, and resulting in better patient outcomes.